1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
Date of Report (Date of earliest event reported):
JUNE 24, 1997
CAMBRIDGE NEUROSCIENCE, INC.
----------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-19193 13-3319074
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
ONE KENDALL SQUARE, BUILDING 700, CAMBRIDGE, MA 02139
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 225-0600
--------------
Total Number of Pages 6.
Exhibit Index at Page 4.
================================================================================
2
Item 5 - Other Events
- ---------------------
On June 24, 1997, Cambridge NeuroScience, Inc. (the "Company") issued a
news release announcing the temporary suspension in the accrual of new patients
in the Phase III trial of CERESTAT(1) in stroke patients, pending the completion
of an expanded benefit to risk analysis of the patients enrolled to date. The
information contained in this news release is incorporated herein by reference
and filed as Exhibit 99.4 hereto.
Item 7 - Financial Statements and Exhibits
- ------------------------------------------
(c) Exhibits.
99.4 The Company's News Release dated June 24, 1997.
- -----------------------
(1) CERESTAT is a registered trademark of Boehringer Ingelheim International
GmbH.
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CAMBRIDGE NEUROSCIENCE, INC.
Date: June 24, 1997 /s/ Harry W. Wilcox, III
----------------------------------------
Harry W. Wilcox, III
Sr. Vice President, Finance and Business
Development; Chief Financial Officer
3
4
EXHIBIT INDEX
-------------
Exhibit
Sequential
Number Description
- ------ -----------
99.4 The Company's News Release dated June 24, 1997.
4